β-Indolyloxy Functionalized Aspartate Analogs as Inhibitors of the Excitatory Amino Acid Transporters (EAATs).
Journal
ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073
Informations de publication
Date de publication:
12 Nov 2020
12 Nov 2020
Historique:
received:
22
06
2020
accepted:
26
08
2020
entrez:
20
11
2020
pubmed:
21
11
2020
medline:
21
11
2020
Statut:
epublish
Résumé
The excitatory amino acid transporters (EAATs) mediate uptake of the major excitatory neurotransmitter l-glutamate (Glu). The essential functions governed by these transporters in regulating the central Glu level make them interesting therapeutic targets in a wide range of neurodegenerative and psychiatric disorders. l-Aspartate (Asp), another EAAT substrate, has served as a privileged scaffold for the development of EAAT inhibitors. In this study, we designed and synthesized the first β-indolyloxy Asp analogs
Identifiants
pubmed: 33214831
doi: 10.1021/acsmedchemlett.0c00342
pmc: PMC7667874
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2212-2220Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
J Med Chem. 2018 Sep 13;61(17):7741-7753
pubmed: 30011368
Neuropharmacology. 2005 Nov;49(6):850-61
pubmed: 16183084
J Chem Inf Model. 2008 Jan;48(1):1-24
pubmed: 18183967
ChemMedChem. 2008 Feb;3(2):302-15
pubmed: 18038380
Curr Opin Pharmacol. 2015 Feb;20:116-23
pubmed: 25466154
J Neurosci. 1994 Sep;14(9):5559-69
pubmed: 7521911
Mol Pharmacol. 2004 Apr;65(4):1008-15
pubmed: 15044631
Curr Top Med Chem. 2006;6(17):1897-906
pubmed: 17017964
J Org Chem. 2013 Sep 20;78(18):9291-302
pubmed: 24004185
Physiol Rev. 2013 Oct;93(4):1621-57
pubmed: 24137018
J Neurosci. 1992 Jan;12(1):56-61
pubmed: 1345946
ACS Chem Neurosci. 2016 May 18;7(5):534-9
pubmed: 26918289
ACS Chem Neurosci. 2017 Aug 16;8(8):1668-1672
pubmed: 28414419
Org Biomol Chem. 2017 Mar 21;15(11):2341-2344
pubmed: 28244539
J Med Chem. 2016 Oct 13;59(19):8757-8770
pubmed: 27626828
J Med Chem. 2016 Oct 13;59(19):8771-8786
pubmed: 27636002
J Am Chem Soc. 2005 Jun 29;127(25):9285-9
pubmed: 15969611
J Neurochem. 1972 Nov;19(11):2657-66
pubmed: 4404455
Expert Opin Ther Targets. 2009 Jun;13(6):719-31
pubmed: 19456273
J Med Chem. 2009 Apr 23;52(8):2311-6
pubmed: 19301898
Nat Chem. 2012 Apr 29;4(6):478-84
pubmed: 22614383
J Biol Chem. 1997 Aug 15;272(33):20336-9
pubmed: 9252337
Int J Dev Neurosci. 1990;8(2):209-16
pubmed: 1970220
Am J Med Genet B Neuropsychiatr Genet. 2012 Jan;159B(1):30-7
pubmed: 22095641
Bioorg Med Chem Lett. 2000 Nov 6;10(21):2407-10
pubmed: 11078189
Nature. 2000 Jan 20;403(6767):316-21
pubmed: 10659851
J Physiol. 1991 May;436:169-93
pubmed: 1676418
Biochem Pharmacol. 2004 Jun 1;67(11):2115-27
pubmed: 15135308
J Med Chem. 2006 Nov 2;49(22):6532-8
pubmed: 17064071
Nat Rev Drug Discov. 2004 Nov;3(11):935-49
pubmed: 15520816
Mol Pharmacol. 1992 Jun;41(6):1124-9
pubmed: 1319548
ACS Chem Neurosci. 2018 Mar 21;9(3):522-534
pubmed: 29140675
J Med Chem. 2010 Oct 14;53(19):7180-91
pubmed: 20857912
Mol Pharmacol. 1998 Feb;53(2):195-201
pubmed: 9463476
Science. 1997 Jun 13;276(5319):1699-702
pubmed: 9180080
J Med Chem. 2009 Feb 26;52(4):912-5
pubmed: 19161278
Mol Pharmacol. 2005 Oct;68(4):974-82
pubmed: 16014807
Nature. 2017 Apr 27;544(7651):446-451
pubmed: 28424515
Prog Neurobiol. 2001 Sep;65(1):1-105
pubmed: 11369436
ACS Chem Neurosci. 2019 Oct 16;10(10):4414-4429
pubmed: 31573179
ChemMedChem. 2008 Jan;3(1):79-90
pubmed: 17990250
Neurology. 2010 Jan 19;74(3):259-64
pubmed: 20083803
Pharmacol Ther. 2005 Sep;107(3):271-85
pubmed: 16112332
Annu Rev Pharmacol Toxicol. 1999;39:431-56
pubmed: 10331091